Want to see GB:PYC full AI Analyst Report?
PYC Stock Chart & Stats
0.28 p
0.05 p(6.45%)
At close: 4:00 PM EST
0.28 p
0.05 p(6.45%)
Day’s Range― - ―
52-Week Range0.25 p - 0.80 p
Previous CloseN/A
Volume16.21M
Average Volume (3M)2.43M
Market Cap
£2.49M
Enterprise Value1.34M
Total Cash (Recent Filing)£257.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetA debt-free capital structure gives durable financial flexibility, lowering insolvency and interest-rate risk. For a cash-burning biotechs, zero debt reduces immediate refinancing pressure and extends runway, allowing management to prioritize operational scaling or selective R&D investments.
Significant Revenue ReboundA 51% revenue rebound signals meaningful commercial traction and demand for the company's modelling services. Sustained top-line growth supports scale economics, provides runway to invest in platform improvements, and is a prerequisite for durable margin recovery if repeatable across clients and projects.
Specialized, High-barrier Business ModelThe firm's focused oncology modelling expertise creates structural competitive advantages: specialized knowledge, proprietary modelling capability, and long client relationships. High technical barriers and regulatory-relevant outputs can sustain fee-for-service pricing power and recurring project demand over time.
Bears Say
Persistent Cash BurnNegative operating and free cash flow indicate the business is not yet self-funding, creating ongoing reliance on external financing. Over months this consumes liquidity, forces management to seek capital or cut investment, and elevates execution risk if revenue momentum weakens.
Ongoing Losses And Negative MarginsSustained net losses and deeply negative margins limit the firm's ability to self-fund growth or absorb project variability. Without consistent margin improvement or higher-margin recurring revenue, profitability risks persist and hinder long-term reinvestment and shareholder value creation.
High Dilution / Funding Risk And Negative ReturnsA very negative ROE and a modest equity base imply future financing could materially dilute shareholders. Continued losses will likely force equity raises or expensive capital terms, reducing per-share value and constraining long-term incentive alignment for investors and management.
Physiomics News
PYC FAQ
What was Physiomics PLC’s price range in the past 12 months?
Physiomics PLC lowest share price was 0.25 p and its highest was 0.80 p in the past 12 months.
What is Physiomics PLC’s market cap?
Physiomics PLC’s market cap is £2.49M.
When is Physiomics PLC’s upcoming earnings report date?
Physiomics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 70 days.
How were Physiomics PLC’s earnings last quarter?
Physiomics PLC released its earnings results on Feb 16, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Physiomics PLC overvalued?
According to Wall Street analysts Physiomics PLC’s price is currently Overvalued.
Does Physiomics PLC pay dividends?
Physiomics PLC does not currently pay dividends.
What is Physiomics PLC’s EPS estimate?
Physiomics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Physiomics PLC have?
Physiomics PLC has 453,208,700 shares outstanding.
What happened to Physiomics PLC’s price movement after its last earnings report?
Physiomics PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Physiomics PLC?
Currently, no hedge funds are holding shares in GB:PYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Physiomics PLC
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsourced quantitative pharmacology and computational biology. They deliver comprehensive modeling, simulation, and data analysis services primarily focused on oncology research and development, utilizing their proprietary Virtual Tumour predictive software. Additionally, Physiomics is engaged in developing innovative technologies for applications within the field of personalized medicine.